Edwards Lifesciences Corporation E1WL34.SA · Stock Open Edwards Lifesciences Corporation in new tab
Edwards Lifesciences Corporation Analysis (E1WL34.SA)
Is Edwards Lifesciences Corporation a good investment? Edwards Lifesciences Corporation (E1WL34.SA) is currently trading at 100.30 BRL.
In terms of valuation, the stock trades at a P/E ratio of 28.57. This valuation is generally in line with the broader market.
Earnings Schedule: Edwards Lifesciences Corporation is expected to release its next earnings report on Oct. 24, 2024.
Investor FAQ
Does Edwards Lifesciences Corporation pay a dividend?
No, it does not currently pay a dividend.
What asset class is Edwards Lifesciences Corporation?
Edwards Lifesciences Corporation is classified as a Stock. You can compare it against 6 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Oct. 24, 2024. The company currently has a trailing EPS of 3.40.
Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
| Split Date | Split Ratio to 1 |
|---|---|
| June 1, 2020 | 3:1 |
Community Discussion